---
schema_version: "secwatch.filing_event.v1"
accession: "0001339970-26-000042"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2026-07-31T20:44:28+00:00"
generated_at: "2026-07-31T20:45:07.066283+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# aTyr Pharma regains global rights to efzofitimod after Kyorin termination

## Summary
- Kyorin terminated collaboration; aTyr and Kyorin entered termination agreement effective July 30, 2026.
- Exclusive rights to develop and commercialize efzofitimod in Japan revert to aTyr.
- aTyr now holds global rights to efzofitimod for all forms of interstitial lung disease.
- Termination includes wind-down of ancillary agreements and transfer of data and orphan drug designation.
- No outstanding payments from Kyorin to aTyr regarding development costs.

## SEC filing metadata
- accession: 0001339970-26-000042
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2026-07-31T20:44:28+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000042/0001339970-26-000042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000133997026000042/atyr-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001339970-26-000042
- JSON: https://secwatch.observer/filing/0001339970-26-000042.json
- Plain text: https://secwatch.observer/filing/0001339970-26-000042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.